Background
==========

Since the introduction of highly active antiretroviral therapy (HAART) gender differences on HIV therapies have been reported including (i) time of HAART initiation \[[@B1]\], (ii) adherence and toxicity to antiretroviral drugs \[[@B2]-[@B4]\], and (iii) virological and immunological response to HAART \[[@B5],[@B6]\] .

Despite the reported gender differences and differences in circulating blood volume and body weight, current treatment goals and dosage of antiretrovirals are equivalent in HIV-1 (HIV) positive women and men \[[@B7]\]. One of the reasons for this may be that women are underrepresented in many HIV clinical trials. In fact, according to a large metaanalysis of 43 randomized clinical trials from 2000--2008 women only accounted for 20% of 22,411 HIV positive subjects \[[@B8]\].

A reduced tolerability of antiretroviral drugs in women compared to men has been reported \[[@B2]\]. Poor tolerability can affect adherence and an association between female gender and reduced rate of adherence to HAART has been described \[[@B3],[@B4]\], but findings are inconsistent and depends on the composition of the studied cohort \[[@B4]\].

Most women with HIV in Europe and the US are of childbearing age and the intention for childbearing is high in this population \[[@B9],[@B10]\]. Thus when prescribing HAART one must consider pregnancy and avoid drugs that are not recommended for early antenatal use e.g. efavirenz and didanosine.

Because of the significant reduction in mortality and rate of disease progression following HAART \[[@B11],[@B12]\], surrogate markers of disease progression such as viral load and CD4 count have been introduced \[[@B13],[@B14]\].

Most studies report no gender-related differences in terms of virological and immunological response to HAART, however data are conflicting \[[@B2],[@B6],[@B8],[@B15]\].

In the present study we used a nationwide, population based cohort of heterosexually infected individuals to estimate gender differences in initiation of HAART regarding timing, regimen and modifications. Moreover, we aimed to estimate the effectiveness of HAART by means of viral load and CD4 count in genders in a setting with free access to HAART and healthcare.

Methods
=======

Setting
-------

Denmark has a population size of 5.6 million \[[@B16]\] and an estimated HIV prevalence among adults of 0.1% \[[@B17]\]. Medical care, including HAART, is tax-paid and provided free-of-charge to all HIV-infected residents in Denmark. Treatment of HIV-infected patients is restricted to eight specialized medical centres, where patients are seen on an outpatient basis at intended intervals of 12--24 weeks. National criteria for initiation of HAART are: (i) acute HIV-infection, (ii) HIV-related disease or an AIDS defining illness (ADI), (iii) pregnancy, (iv) until 1 May 2008 a CD4 count below 300 cells/μl and hereafter a CD4 count below 350 cells/μl and (v) until 31 December 2001 HIV-1 RNA \> 100,000 copies/mL \[[@B18]\].

The Civil Registration System (CRS)
-----------------------------------

The CRS is a national registry of all Danish residents containing information on date of birth, sex, address, date of migration and date of death. At birth or immigration a 10-digit personal number is assigned to each individual (CPR), which enables treatment centres to avoid multiple registrations of the same patient. We used the CPR to link data from the CRS to the Danish HIV Cohort Study.

Danish HIV Cohort Study (DHCS)
------------------------------

The DHCS is a prospective, observational, nationwide, multicentre population-based cohort study of all HIV-infected patients seen at the Danish HIV clinics since 1 January 1995. The cohort has been described in details elsewhere \[[@B19]\]. In brief, the data collection is ongoing, with continuous enrolment of both newly diagnosed residents and immigrants with HIV. The database is updated annually and among other variables it contains data on: date of birth, gender, route of transmission, race, date of first HIV-1 positive test, bodyweight, immigration and emigration, date of death, date of HAART initiation, HAART regimens and reasons for modifications. Laboratory data include cumulative CD4 counts and HIV RNA among others. Status of pregnancy was extracted from the Danish National Hospital Database.

Ethics
------

The study has been approved by the Danish Data Protection Agency (jr. 2001-41-0624).

The DHCS is approved by the Danish Data Protection Agency. Since data collection did not involve direct patient contact the study was not subject to approval by the Danish Research Ethics Committee.

Study population
----------------

We describe two cohorts in this study: Cohort 1: Heterosexually infected adult women and men diagnosed with HIV in Denmark from 1 January 1997 to 31 December 2009 with no record of Hepatitis C (HCV) infection. Cohort 2: Patients in the above mentioned cohort initiating HAART from 1 January 1997 to 31 December 2009.

Definitions
-----------

HAART was defined as the combination of antiretroviral treatment with at least three drugs, including at least one non-nucleoside reverse-transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), and/or abacavir, or a treatment regimen with a combination of a NNRTI and a boosted PI \[[@B18]\]. We categorized treatment modifications into 3 groups: virological failure, toxicity (covering: abnormalities of body fat distribution, dyslipidaemia, hypersensitivity, gastrointestinal toxicity, neurological toxicity, nephrological toxicity, endocrinological toxicity and other toxicity) and other/unknown (covering: patient's wish, doctor's decision, other cause, unknown, as part of modification to another HAART, problems with adherence). Data were based on medical files.

Virological failure was defined as such if the physician treating the patients' HIV infection had stated virological failure as the reason for modification in the medical file.

Undetectable viral load was defined as a plasma HIV RNA load of \<500 copies/mL, which was the highest level of sensitivity for testing in the observation period. We defined acute HIV infection as clinical seroconversion with a positive Western blot pattern.

CD4 count and HIV RNA at HAART initiation were defined as the latest value measured before initiation of therapy. Hepatitis B (HBV) co-infection was defined as being hepatitis B surface antigen (HbsAg) positive.

Statistical analyses
--------------------

Start of the observation period for cohort 1 was defined as date of eligibility for therapy as described above and patients were followed to initiation of HAART, emigration, death or 31 December 2009, whichever came first. Cohort 1 is used in the analysis of time from eligibility for therapy to HAART initiation.

In cohort 2 patients were observed from date of HAART initiation and censored at emigration, death or 31 December 2009, whichever came first. Cohort 2 was studied in all analyses, but timing of HAART initiation.

A patient was considered eligible for therapy the day they fulfilled one of the above mentioned national criteria concerning CD4 count, HIV RNA or AIDS.

The incentive for initiation of HAART during pregnancy, acute HIV infection and in HBV coinfection is different than in patients starting HAART due to an impaired immune system, i.e. low CD4 count. In the analysis of time from eligibility to HAART initiation we therefore excluded patients initiating HAART before they were eligible for therapy.

Information on initiation of HAART due to non-AIDS defining HIV related disease was not available in the DHCS and therefore not assessed in the analysis of being eligible for start of HAART. When studying the actual number of patients initiating HAART during acute HIV infection this was defined as a patient with acute HIV infection initiating therapy during the first 3 months after HIV diagnosis.

Intergroup characteristics were compared using Wilcoxon rank sum test for continuous variables and chi-square test and Fisher's exact test for categorical variables. Median and interquartile ranges (IQR) were determined for continuous variables. The CD4 count at initiation of HAART was subsequently log-transformed and analysed in linear regression adjusting for age, ethnicity and period of initiation. AIDS was not included in this analysis as covariate, since the CD4 count and AIDS are dependent covariates. Likewise, viral load at initiation of HAART was log-transformed and analysed in linear regression adjusting for age, ethnicity, period of initiation and prior or current AIDS at start of HAART.

To assess linearity, continuous variables were entered in the model as second degree polynomials and reduced as appropriate. Significance level was set at 0.05 (two-sided).

To evaluate the response to HAART, the CD4 and HIV RNA values were grouped in 12-week intervals and computed as described elsewhere \[[@B20]\]. The absolute CD4 counts were log-transformed and analysed in linear regression and adjusted as mentioned above at 1 year (48 weeks), 3 years (156 weeks) and 6 years (312 weeks). Furthermore, we estimated the proportion of patients achieving an undetectable viral load during follow-up. Logistic regression model was used to compare prevalence of detectable viral load between genders at year 1, 3 and 6. Odds ratios (OR's) and correlating 95% confidence intervals (CI) were estimated and adjusted for age, ethnicity, period of initiation and prior or current AIDS at initiation of HAART. The validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test.

The cumulative incidence function with death as a competing risk were computed for time from eligibility of therapy to HAART initiation. To estimate the hazard ratio (HR) and associated 95% CI, we used Cox proportional hazards models and adjusted for race and time-updated age (18--29, 30--39, 40--49, 50--59, 60--69 and 70--100 years). Due to non-proportionality of period of initiation the analysis was stratified for period of initiation of HAART.

In the sensitivity analyses women initiating HAART due to pregnancy, women were excluded if date of HAART initiation was within the period of one year before the conception (estimated as 37 weeks before delivery) or during pregnancy.

Two periods: 1997--2002 (the early HAART period) and 2003--2009 (the late HAART period) and five initial HAART regimens were assessed for analysis in this study: i) 3 nucleoside reverse transcriptase inhibitors (NRTI's), ii) 2 NRTI's + efavirenz, iii) 2 NRTI's + nevirapine, iv) 2 NRTI's + PI/ritonavir or PI and v) other HAART regimen.

Poisson regression analyses were used to estimate IR, IRR and corresponding 95% CI of the first modification of treatment due to toxicity and other/unknown the first year after initiation of HAART and were adjusted by time-updated age (18--29, 30--39, 40--49, 50--59, 60--69, 70--100 years), race, time-updated CD4 count (\<200, 200--350 and \>350 cells/μl), time-updated viral load (\< 50,000, 50,000-100,000 and \> 100,000 copies/mL), prior or current AIDS at HAART initiation, body weight (\<50, 50--70, 71--100 and \>100 kg), initiation period \< 1 January 2003 and \>= 1 January 2003. Modification due to failure could not be assessed because of small numbers.

A composite table was computed with reasons for switching due to toxicity. In these analyses a patient could only contribute with one modification of each reason. In each category with more than five changes of regimen IR's and corresponding 95%CI and IRR's and corresponding 95%CI adjusted for the same confounders as mentioned above in the analyses of IRR.

The cumulative incidence function of time from eligibility to HAART initiation were done using R-2.12.2 \[[@B21]\] and the cmprsk library by Bob Gray.

SAS statistical software version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for data analysis.

Results
=======

Time from eligibility to HAART initiation
-----------------------------------------

A total of 1170 heterosexually infected women and men reached eligibility for HAART. Subsequently, HAART was initiated in 473 (52.1%) women and in 435 (47.9%) men during follow-up (Figure  [1](#F1){ref-type="fig"}). Figure  [2](#F2){ref-type="fig"} presents curves for time from eligibility to initiation of HAART stratified by gender. We found no difference in time to initiation of HAART between genders (HR 0.91 95% CI, 0.79-1.06, unadjusted *p*=0.98, adjusted *p*=0.21 (women vs. men).

![Flowchart of HIV infected patients in the Danish HIV Cohort Study.](1471-2334-12-293-1){#F1}

![The cumulative incidence function with death as a competing risk for time from eligibility of therapy to HAART initiation stratified by gender.](1471-2334-12-293-2){#F2}

Patient characteristics
-----------------------

Clinical and demographic characteristics at initiation of HAART are presented in Table  [1](#T1){ref-type="table"}. Total follow-up: 5352 person-years. Women were younger, a greater proportion of women were of Black and Asian ethnicity (*p*\<0.0001) and had acquired HIV abroad (*p*\<0.0001). Women initiated HAART at higher CD4 counts (adjusted *p*=0.026) and lower viral loads (adjusted *p*=0.0003). Fifty-nine women (12.5%) initiated HAART due to pregnancy. When repeating the analysis excluding women who initiated HAART due to pregnancy there was no difference in median CD4 counts at initiation of HAART (adjusted *p*=0.21). Prior or current AIDS and acute HIV infection at HAART initiation were more frequent in men. During the late HAART era women were more likely to receive a HAART regimen comprising 2 NRTI's + either PI/r or unboosted PI (29.1% vs. 9.0%), and less likely to initiate a 2 NRTI's + efavirenz based regimen (59.8% vs. 80.3%) than men (*p*\<0.0001). This difference was not significant when women initiating HAART due to pregnancy were excluded.

###### 

Patient characteristics at initiation of HAART stratified by gender (n = 908)

                                                                             **Women**                 **Men**                    ***[p-value]{.ul}***^***[1]{.ul}***^
  -------------------------------------------------------------------------- ------------------------- -------------------------- --------------------------------------
  Subjects, n(%)                                                             473 (52.1)                435 (47.9)                 \-
  Follow-up from initiation of HAART (years), median (IQR)                   5.9 (3.2-8.7)             5.7 (2.7-8.5)              \-
  Follow-up time from initiation of HAART, (person-years)                    2833                      2519                        
  Age in years at HAART initiation, median (IQR)                             33.0 (28.6-40.1)          43.2 (35.3-51.7)           \<0.0001
  Race, n(%)                                                                                                                       
   White                                                                     137 (29.0)                319 (73.7)                 \<0.0001
   Asian                                                                     76 (16.1)                 12 (2.8)                   
   Black                                                                     250 (53.0)                90 (20.8)                  
   Other                                                                     9 (1.9)                   12 (2.8)                   
   (missing)                                                                 \(1\)                     \(2\)                      
  Place of HIV transmission, n(%)                                                                                                  
   Denmark                                                                   127 (28.5)                150 (38.3)                 \<0.0001
   Europe + US                                                               19 (4.3)                  29 (7.4)                   
   Africa                                                                    224 (50.3)                140 (35.7)                 
   Asia                                                                      72 (16.2)                 63 (16.1)                  
   Other                                                                     3 (0.7)                   10 (2.6)                   
   (missing)                                                                 \(28\)                    \(43\)                     
  CD4 cell count at HAART initiation (cells/μl), median (IQR)                                                                      
  All women included                                                         196 (90--290)             180 (63--290)              0.12 (0.026)
  Pregnant women excluded                                                    170 (80--270)             180 (63--290)              0,87 (0,21)
  HIV-RNA at HAART initiation (copies/mL), median (IQR) All women included   50,800 (12,500-204,000)   126,155 (32,200-501,000)   \<0.0001 (0.0003)
  Pregnant women excluded                                                    61,320 (16,519-237,000)   126,155 (32,200-501,000)   \<0.0001 (0.0066)
  Acute HIV infection at HAART initiation, n(%)                              4 (0.9)                   15 (3.5)                   0.0089
  AIDS before HAART initiation, n(%) All women included                      88 (18.6)                 106 (24.4)                 0.034
  n(%) of all patients except pregnant women Pregnant women excluded         87 (21.8)                 106 (24.4)                 0.37
  Pregnant at HAART initiation, n(%)                                         59 (12.5)                 \-                         \-
  Antiretroviral therapy before HAART, n(%)                                  14 (3.0)                  12 (2.8)                   0.86
  Hepatitis B co-infection^2^, n(%)                                          30 (6.3)                  20 (4.6)                   0.25
  Hepatitis C co-infection^3^, n(%)                                          0 (0)                     \-                         \-
  First-line HAART 01.01.1997 -- 31.12.2002 All women included                                                                     
   3 NRTI's^4^                                                               21 (9.5)                  9 (4.3)                    0.29
   2 NRTI's + efavirenz                                                      71 (32.0)                 76 (35.9)                  
   2 NRTI's + nevirapine                                                     7 (3.2)                   6 (2.8)                    
   2 NRTI's + PI's^5^                                                        93 (41.9)                 94 (44.3)                  
   Other regimen                                                             30 (13.5)                 27 (12.7)                  
  Pregnant women excluded                                                                                                          
   3 NRTI's                                                                  21 (11.1)                 9 (4.7)                    0.13
   2 NRTI's + efavirenz                                                      66 (37.7)                 76 (39.8)                  
  2 NRTI's + nevirapine                                                      5 (2.6)                   6 (3.1)                    
   2 NRTI's + PI's                                                           73 (38.4)                 94 (44.3)                  
   Other regimen                                                             25 (13.2)                 27 (12.7)                  
  First-line HAART 01.01.2003 -- 31.12.2009 All women included                                                                     
   3 NRTI's                                                                  3 (1.2)                   1 (0.5)                    \<0.0001
   2 NRTI's + efavirenz                                                      150 (59.8)                179 (80.3)                 
   2 NRTI's + nevirapine                                                     17 (6.8)                  13 (5.8)                   
   2 NRTI's + PI's                                                           73 (29.1)                 20 (9.0)                   
   Other regimen                                                             8 (3.2)                   10 (4.5)                   
  Pregnant women excluded                                                                                                          
   3 NRTI's                                                                  3 (1.4)                   1 (0.5)                    0.066
   2 NRTI's + efavirenz                                                      148 (70.5)                179 (80.3)                 
   2 NRTI's + nevirapine                                                     15 (7.1)                  13 (5.8)                   
   2 NRTI's + PI's                                                           36 (17.1)                 20 (9.0)                   
   Other regimen                                                             8 (3.8)                   10 (4.5)                    

Figures are number (%) or median (interquartile range - IQR).

^1^*P*-values were calculated using chi-square or Fisher's exact test (when appropriate) for categorical variables and Kruskal-Wallis test for continuous variables. CD4 cell counts and viral loads were subsequently analysed by linear regression adjusting for age and race (*p*-value in parenthesis). ^2^ Patients with positive Hbs-Ag in the study period, ^3^ Hepatitis C was an exclusion criteria, ^4^ Nucleoside reverse transcriptase inhibitors (NRTI), ^5^ Protease Inhibitors (PI's).

Modification of HAART
---------------------

During the first year after initiation of HAART, gender had no impact on risk of first modification of treatment due to either toxicity (adjusted incidence rate ratio women vs. men, IRR, 0.97 95% confidence interval (CI) 0.66-1.44) or other/unknown reasons (adjusted IRR women vs. men 1.18 95% CI, 0.76-1.85) (Table  [2](#T2){ref-type="table"}). Nor did the estimates change when we excluded bodyweight (data not shown). Only 5 (1.3%) women and 4 (1.5%) men switched HAART regimen because of virological failure and therefore this aspect was not further explored.

###### 

Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of reasons of treatment modifications the first year after initiation of HAART according to gender

                                           **Toxicity IR (95% CI)**   ***Other/Unknown*IR (95% CI)**   **Toxicity IRR (95% CI)**   ***Other/Unknown*IRR (95% CI)**
  ---------------------------------------- -------------------------- -------------------------------- --------------------------- ---------------------------------
  *Adjusted for all listed confounders,*                                                                                            
  Men                                      0.52 (0.42-0.64)           0.55 (0.44-0.68)                 1.00                        1.00
  Women                                    0.49 (0.41-0.59)           0.57 (0.48-0.67)                 0.97 (0.66-1.44)            1.18 (0.76-1.85)
  Women (pregnant excluded)                0.54 (0.45-0.66)           0.49 (0.40-0.61)                 1.03 (0.69-1.52)            1.14 (0.71-1.82)

Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count, time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (\< January 1^st^ 2003 and \>= January 1^st^ 2003).

Overall, the four most common reasons for change of HAART were hypersensitivity, gastrointestinal toxicity, neurological toxicity and other toxicity (Figure  [3](#F3){ref-type="fig"}). Women were more likely to modify their treatment due to gastrointestinal toxicity (9.1% vs. 4.6%, *p*=0.0078). However, the adjusted IRR of risk of switching did not exhibit gender differences (Table  [3](#T3){ref-type="table"}).

![Number of patients reporting modification of HAART during the first year after initiation due to toxicity for the reasons listed.](1471-2334-12-293-3){#F3}

###### 

Incidence rates, IR (per 1 person-year), incidence rates ratios, IRR, of risk of treatment modification due to different types of toxicities

  **Incidence rates and incidence rate ratios for changes in HAART during the first year due to the following reasons:**   **Women IR 95%(CI)**   **Men IR 95%(CI)**   **Women vs. men (ref) unadjusted IRR 95%(CI)**   **Women vs. men (ref) adjusted IRR 95%(CI)**
  ------------------------------------------------------------------------------------------------------------------------ ---------------------- -------------------- ------------------------------------------------ ----------------------------------------------
  Toxicity, hypersensitivity                                                                                               0.09 (0.06-0.15)       0.06 (0.03-0.14)     1.43 (0.58-3.52)                                 −^1^
  Toxicity, gastrointestinal                                                                                               0.22 (0.16-0.15)       0.16 (0.10-0.26)     1.37 (0.80-2.36)                                 0.97 (0.49-1.93)
  Toxicity, neurological                                                                                                   0.19 (0.13-0.27)       0.20 (0.13-0.30)     0.96 (0.56-1.64)                                 1.48 (0.65-3.38)
  Toxicity, other                                                                                                          0.18 (0.13-0.25)       0.29 (0.21-0.40)     0.62 (0.39-1.00)                                 −^1^

^1^ No estimate available, due to shortage of events.

Poisson regression analyses of incidence rates, IR (95% CI), and incidence rates ratios, IRR (95% CI), adjusted by time-updated age, race, time-updated CD4 count, time-updated viral load, prior or current AIDS at HAART initiation, body weight and initiation period (\< January 1st 2003 and \>= January 1st 2003).

Response to HAART
-----------------

We estimated the proportion of patients with an undetectable viral load after initiation of HAART (Figure  [4](#F4){ref-type="fig"}). One year after initiation of HAART 83% of women and 92% of men had gained viral control (viral load \< 500 copies/ml), adjusted OR 1.24 (95%CI 0.72-2.14). After 3 and 6 years the proportion of women and men with an undetectable viral load was 82% and 87%, respectively, adjusted OR 0.92 (95%CI 0.53-1.61), and 83% and 87%, respectively, adjusted OR 0.87 (95%CI 0.41-1.84)

![Proportion of patients with an undetectable viral load during the study period.](1471-2334-12-293-4){#F4}

We found no statistically significant differences in median CD4 count between genders after initiation of HAART. At year 1 the median CD4 count was 330 cells/μl IQR(210--457) in women and 360 cells/μl IQR(220--510) in men (adjusted *p*=0.90) at 3 years 459 cells/μl IQR(316--600) in women and 469 cells/μl IQR(318--656) in men (adjusted *p*=0.90) and at 6 years 530 cells/μl IQR(380--696) in women and 582 cells/μl IQR(382--793) in men, (adjusted *p*=0.90) (Figure  [5](#F5){ref-type="fig"}).

![Absolute CD4 count during the study period.](1471-2334-12-293-5){#F5}

Discussion
==========

Trial data on HIV therapies in women are limited \[[@B8]\] and discrepant results regarding the impact of gender on HAART have been reported \[[@B2]\]. Here, we found that in a setting with free access to healthcare and HAART gender did neither affect time from eligibility to HAART, modification of therapy nor virological and immunological response to HAART.

In line with our study, European cohorts report no gender differences in time from eligibility to initiation of therapy \[[@B22],[@B23]\], while in the US a propensity to delay HAART in women compared to men is seen \[[@B24]-[@B26]\]. Though, studies defined eligibility differently the estimated differences could be attributed to the reported inequality in access to HAART and healthcare in the US more than gender itself \[[@B27]\]. In Europe, overall there is equality in access to HAART between genders, though in central and eastern Europe women tends to be favored over men \[[@B28]\].

The enormous benefit of HAART is reflected by few clinical outcomes \[[@B12],[@B29]\] and therefore we assessed clinical progression by means of the virological and immunological response in patients seen after initiation of HAART. Additionally, we have earlier reported that in Denmark no major differences in terms of progression to AIDS and death are seen between men who have sex with men (MSM), heterosexually infected men and heterosexually infected women \[[@B30]\]. Therefore we decided to focus on HIV positive patients infected heterosexually to study patients living in the same social context \[[@B6]\].

We excluded intravenous drug users and HCV coinfected patients, since studies repeatedly report worse clinical outcomes \[[@B31]-[@B33]\] and weaker immunological and virological responses in these patients \[[@B22],[@B34]\]. Furthermore, due to concerns about residual confounding when adjusting for IDU in the model, we chose to perform restricted analyses with exclusion of this group of patients.

Data on gender differences in CD4 count recovery after initiation of HAART are discrepant. In agreement with others \[[@B6],[@B14],[@B15],[@B22]\] we found no differences in CD4 recovery. On the contrary several studies report a beneficial immunological outcome in women \[[@B5],[@B35]-[@B37]\].

The lower viral load seen in women at initiation of therapy even when we excluded pregnant women is supported by several studies \[[@B2],[@B3],[@B15],[@B22],[@B35],[@B38],[@B39]\] and probably has no influence on disease progression \[[@B2]\]. Compared to other cohorts \[[@B5]\] where HIV RNA was undetectable in 48-79% of all patients a relatively high proportion of our patients (83% of women and 92% of men) had undetectable viral load after 1 year, though, different definitions of viral suppression make studies difficult to compare.

We found no difference in virological response during follow-up between men and women, which is in accordance with earlier reports on gender differences \[[@B1],[@B15],[@B22]\], however during the entire follow-up the proportion of men who had gained full viral control was greater than that of women.

Only a small part of patients were ART experienced before HAART initiation and this proportion did not differ between genders. Along with others \[[@B5]\], we found that women were less likely to receive a HAART regimen containing efavirenz. Since the publication of teratogenicity in animal studies \[[@B40]\] and of neural tube defects in infants exposed to efavirenz in their first trimester \[[@B41]\] guidelines have recommended avoiding this drug in women likely to conceive. Indeed, after excluding women who initiated HAART due to pregnancy from our analysis the initial HAART regimen did not differ significantly between genders.

Regarding pharmacokinetics on HAART, data are limited, but current evidence suggests that gender differences exist \[[@B42]\]. Reportedly, women have been found to be more likely to discontinue ART due to neurological \[[@B39]\] and dermatologic symptoms \[[@B3],[@B23],[@B43]\]. Furthermore, an increased risk of lactic acidosis \[[@B44]\], HIV lipodystrophy \[[@B23],[@B45]\] and hepatic dysfunction \[[@B46]\] have been reported in women. Some have speculated that the higher rate of adverse effects in women are caused by a higher drug exposure in women \[[@B35]\].

Our multivariate model failed to show more treatment modifications in women of the original HAART regimen the first year after initiation compared to men. This finding is supported by others \[[@B3],[@B6],[@B8]\]. Because dosing regimens of HAART are not gender specific, we adjusted for bodyweight in the analysis of IRR for treatment modifications and this did not alter results. Nor exclusion of pregnant women changed results significantly.

In contrast to our study four studies \[[@B23],[@B37],[@B47],[@B48]\] found that women were more likely to discontinue treatment than men. However, the first two studies have not considered pregnancy and in the latter two women were excluded when becoming pregnant. However, the UK CHIC study was able to take pregnancy into account and in this cohort women were more likely to discontinuate treatment for reasons other than virological failure \[[@B5]\].

We found that women were more likely to change regimen due to gastrointestinal toxicity, though, this information needs to be interpreted with care due to small numbers.

As earlier stated some studies report that women are more likely to change regimen, because of HIV lipodystrophy \[[@B23],[@B45]\]. Since we focus on the first year after initiation of HAART only, we probably do not allow for sufficient time for this to be of clinical significance \[[@B49]\].

The major strength of our study is the nationwide population-based design, linking the nationwide registers DHCS and CRS with minor loss to follow-up \[[@B50]\]**\]** and access to electronically collected longitudinal data on HIV RNA and CD4 counts.

Some limitations need to be assessed. Data on adherence and socioeconomic status are not available in our cohort and are therefore not assessed for analysis. Information on the study participants was those reported by the providers and then retrospectively summarized for this study. In the DHCS only toxicities leading to a modification are documented and therefore the risk of adverse events might be substantially higher than the incidence reported in our study. Moreover, data on virological failure is based on the discretion of the physician and might therefore not reflect the actual number of virological failures.

The route of transmission is self-reported and therefore can be misclassified. Furthermore, infection with HCV and HBV was not treated as a time-updated variable, as this information is not available in DHCS.

Conclusions
===========

In a setting with free access to healthcare and antiretroviral drugs gender has no impact on time to initiation of HAART, modification of therapy the first year or response to HAART. The differences observed between genders are mainly attributable to initiation of HAART in pregnant women.
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